<p>Ascentage-B (06855.HK) announced its full-year results for the year ended December last year, with revenue of RMB 574 million, a year-on-year decrease of 41.5%. Losses widened to RMB 1.243 billion, compared to a loss of RMB 405 million in the same period last year; loss per share was RMB 3.49. No final dividend will be declared</p>

159570

06855

159837

<p>Ascentage-B announced its full-year results for the year ended last December, with a revenue of RMB 574 million, a year-on-year decrease of 41.5%. The loss widened to RMB 1.243 billion, compared to a loss of RMB 405 million in the same period last year; the loss per share was RMB 3.49. No final dividend will be distributed</p>

AASTOCKS

China Universal CNI HK Connect Innovative Drugs Industry ETF

ASCENTAGE-B

E Fund CSI Biotechnology Theme ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

ChinaAMC SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

E Fund CSI 300 Health Care ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Yinhua CSI Innovative Drugs Industry ETF

ChinaAMC CSI Biotechnology Theme ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

China Merchants CSI Biotechnology Theme ETF

Penghua CSI HK Connect Health Care Composite ETF

"Performance" Ascentage Pharma-B's losses widened to 1.243 billion RMB last year